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Summary
Background Information is scarce about biological disease-modifying antirheumatic drug (DMARD) switching 
patterns in children and young people (aged ≤16 years) with juvenile idiopathic arthritis in an era of many biologic 
therapies. The best choice of biologic to use if the first biological DMARD is not beneficial also remains unclear. We 
aimed to quantify and characterise biologic switching patterns in children and young people with juvenile idiopathic 
arthritis, and to compare the effectiveness of using a second tumour necrosis factor inhibitor (TNFi) versus non-TNF 
is following failure of a first TNFi biologic in routine clinical practice.
Methods Our study population comprised patients with juvenile idiopathic arthritis who were enrolled in two parallel 
UK cohort studies (the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study 
[BSPAR-ETN] and the Biologics for Children with Rheumatic Diseases [BCRD] study) between Jan 1, 2004, and 
April 11, 2019. Data on disease characteristics and DMARD therapy were collected at the time of initiation of a first 
biologic, at 6 months, at 1 year, and annually thereafter. Biologic switching patterns were described in all patients who 
started their first biologic from Jan 1, 2010, onwards. Among patients who started treatment with their first biologic 
from Jan 1, 2004, onwards, had polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis 
[positive or negative for rheumatoid factor]), and who had started a second biologic, we assessed changes in outcome 
variables at 6 months compared with baseline and compared the proportion of patients who achieved an American 
College of Rheumatology Pediatric (ACR Pedi) 90 response and minimal disease activity at 6 months on the basis of 
the class of the second biologic (a second TNFi vs non-TNFi biologic). Changes in outcome variables at 6 months were 
compared using linear regression or logistic regression, adjusted for propensity quintiles to account for confounding 
by indication. We used multiple imputation to account for missing data.
Findings Between Jan 1, 2004, and April 11, 2019, 2361 patients were enrolled on initiation of biologic therapy. From 
Jan 1, 2010, onwards, 1152 patients started their first biologic, most of whom started treatment with TNFis (1050 [91%]). 
The median follow-up was 2·2 years (IQR 1·1–3·8). During this time, 270 (23%) of 1152 patients started a second 
biologic, 61 (5%) started a third biologic, and 11 (1%) started a fourth biologic. Among 240 patients with polyarticular-
course juvenile idiopathic arthritis, 194 (81%) started a second TNFi and 46 (19%) started a non-TNFi after an initial 
TNFi had failed. Choice of second treatment (second TNFi vs non-TNFi biologic) did not affect the proportion of 
patients who achieved an ACR Pedi 90 response (adjusted odds ratio [OR] 2·5, 95% CI 0·8–7·9; p=0·11) or minimal 
disease activity (adjusted OR 1·6, 95% CI 0·6–3·8; p=0·33).
Interpretation For many children and young people with juvenile idiopathic arthritis, treatment with a first or second 
biologic is not beneficial. We found no evidence that switching to a second non-TNFi biologic was more beneficial 
than a second TNFi.
Funding Versus Arthritis and The British Society for Rheumatology.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Biological disease-modifying antirheumatic drugs 
(DMARDs), or bio logics, have become a main treat-
ment option in juve nile idio pathic arthritis, particularly 
for individ uals who do not respond to, or are intolerant 
of the con ven tional syn thetic DMARDs, such as metho-
trex ate. The intro duction of biological DMARDs has 
improved patient outcomes, and many more children now 
reach adulthood without substantial joint damage or 
complications from persistent uveitis compared with 
the pre-biologic era.1,2 Tumour necrosis factor inhibitors 
(TNFis), such as etanercept and adalimumab, remain the 
most commonly prescribed biologics for juvenile idio-
pathic arthritis.3 However, several other classes of bio-
logical DMARDs are now avail able, including the T-cell 
co-stimulatory modu lator abata cept, the interleukin (IL)-6 
pathway inhibitor tocilizumab, IL-1 inhibitors (includ ing 
the IL-1 receptor antagonist anakinra and IL-1β inhibitor 
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canakinumab), and the targeted B-cell depleting drug 
rituximab (not licensed for juvenile idio pathic arthritis). 
The anti-IL-1 and anti-IL-6 classes of bio logics are now con-
sidered first-line biologic therapy for child ren and young 
people with systemic juvenile idio pathic arthritis.4
The aim of juvenile idiopathic arthritis treatment is to 
achieve inactive disease or remission, to enable normal 
development and growth.5 Unfortunately for some indi-
viduals, treatment with methotrexate or the first biologic 
prescribed does not result in disease control or is dis-
continued due to adverse events. Some children and young 
people will switch to a second or subsequent biologics 
until disease control is achieved.3 For some individuals, 
disease control is not achieved despite cycling through 
multiple biologics. A 2018 publication about adults with 
rheumatoid arthritis suggested that at least 6% of patients 
received at least three different classes of biologic and 
21% received at least three different biological drugs, often 
including multiple TNFis.6 A Dutch registry of patients 
with juvenile idiopathic arthritis who started etanercept 
as a first biologic before 2010 has previously described 
patterns of biologic switch ing.7 However, these patients 
were recruited when few biologic therapies were available 
and thus might now be outdated.
Until 2015, the prescribing of biological DMARDs in 
the UK was regulated by the National Institute for Health 
and Care Excellence guidance, which stated that biologics 
should be reserved for children with juvenile idiopathic 
arthritis, including systemic juvenile idiopathic arthritis, 
following previous treatment with methotrexate.8,9 In 
2015, National Health Service (NHS) England published a 
new treatment pathway for juvenile idiopathic arthritis, 
which still recom mended treatment with methotrexate 
before biological therapy, with the exception of individ-
uals with enthesitis-related juvenile idiopathic arthritis, 
who were recom mended to start a TNFi, or individuals 
with macrophage activation syndrome non-responsive 
to cortico steroids, who were recommended to initiate 
treatment with ana kinra. After methotrexate, the majority 
of children with juvenile idiopathic arthritis should start 
an initial TNFi, except those with systemic juvenile 
idiopathic arthritis, who are recom mended to start 
tocilizumab. After an initial biologic is ineffective, patients 
with systemic juvenile idiopathic arthritis can switch to 
anakinra, whereas all other patients are recommended to 
start a second TNFi, with the excep tion of patients who are 
positive for rheumatoid factor, who are recommended to 
start rituximab.5
With the increasing availability of other biologic classes, 
the proportion of children and young people with juvenile 
idiopathic arthritis who are switching between biologics 
remains unclear. A better under standing of patients with 
juvenile idiopathic arthritis who switch biologic drugs 
multiple times is vital to better inform future treatment 
guidelines and health economic evaluations. Additionally, 
although it is recog nised that children are switching 
between biologics, no data are available to inform pre-
scribing after patients do not respond to treatment with a 
first biologic, usually a TNFi. As a result of the paucity of 
real-world evidence, at present two conflicting recom-
mendations exist for patients when switching to a sec-
ond biologic due to ineffectiveness of an initial TNFi: 
2015 NHS England guidelines5 suggest treatment with a 
second TNFi and 2019 American College of Rheumatology 
Research in context
Evidence before this study
Biological therapies have become a mainstay of treatment for 
many autoimmune diseases, including juvenile idiopathic 
arthritis. However, not all children and young people respond 
to treatment with the first biologic they are prescribed, and the 
extent to which further exposure to biologics occurs is largely 
unknown. In 2013, Otten and colleagues described patterns of 
biologic switching in a Dutch registry of patients with juvenile 
idiopathic arthritis who started etanercept as their first 
biologic; however, these patients were recruited before 2010, 
when few biologic therapies were available. We searched 
PubMed for studies of biologic therapies in juvenile idiopathic 
arthritis, published between Jan 1, 2000, and Dec 31, 2019, 
using the search terms “biologic*”, and “JIA” (or “juvenile” and 
“arthritis”) and “cohort” or “regist*”. We found no studies 
assessing the next best choice of biologic if the first biologic 
(usually a tumour necrosis factor inhibitor [TNFi]) is 
not beneficial.
Added value of this study
This analysis included children and young people with juvenile 
idiopathic arthritis who were enrolled in one of two UK studies: 
the Biologics for Children with Rheumatic Diseases study and 
the British Society for Paediatric and Adolescent Rheumatology 
Etanercept Cohort Study. Our results showed that biologic 
switching is not uncommon, with more than one-fifth of 
patients starting a second biologic and 5% receiving at least 
three; however, switching often occurred within the same class 
of biologic rather than between different classes of biologic. 
The response to a second biologic was similar between patients 
who switched to a biologic of the same class and those who 
switched to a biologic of a different class.
Implications of all the available evidence
On the basis of these findings, no evidence exists to support or 
refute the 2015 biologic prescribing guidelines of the National 
Health Service (NHS) England, which recommend that the 
majority of patients with juvenile idiopathic arthritis switch to a 
second TNFi, or the 2019 guidelines of the American College of 
Rheumatology, which recommend that patients switch to an 
alternative class of biologic (eg, tocilizumab or abatacept). 
Repeat analysis with a larger sample size is required to validate 
these findings. These data will be used to inform practice 
guidelines, cost-effectiveness, and policy guidelines.
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(ACR) guide lines10 suggest treatment with a different 
class of biologic. The use of real-world data to identify the 
optimum choice of second biologic is methodologically 
challenging because of the potential of confounding 
by indication; patients might be prescribed a certain 
biological therapy due to their characteristics (ie, systemic 
features, disease severity), and thus comparing the 
treatments might be confounded by these characteris-
tics. Therefore, careful statistical approaches must be 
considered.
In this study, we aimed to quantify the proportion of 
children and young people with juvenile idiopathic 
Figure 1: Biologic switching in patients with juvenile idiopathic arthritis (excluding systemic juvenile idiopathic arthritis) who initiated treatment with a 
first biologic from Jan 1, 2010, onwards (n=1055)
TNFi=tumour necrosis factor inhibitor. IL=interleukin.
TNFi
1036 (98%) of 1055 patients
Tocilizumab
18 (2%) of 1055 patients
Rituximab
1 (<1%) of 1055 patients
TNFi
202 (81%) of 250 patients
Tocilizumab
31 (12%) of 250 patients
IL-1 inhibitor 
1 (<1%) of 250 patients
Rituximab
9 (4%) of 250 patients
Abatacept
2 (<1%) of 250 patients
Ustekinumab
1 (<1%) of 250 patients
Tocilizumab
2 (22%) of 9 patients
TNFi
7 (12%) of 57 patients
TNFi
1 (2%) of 57 patients
TNFi
1 (2%) of 57 patients
Rituximab
4 (7%) of 57 patients
TNFi
2 (22%) of 9 patients
Abatacept
3 (33%) of 9 patients
Tocilizumab
33 (58%) of 57 patients
Abatacept
2 (4%) of 57 patients
Abatacept
4 (7%) of 57 patients
Secukinumab
1 (2%) of 57 patients
Secukinumab
1 (<1%) of 250 patients
TNFi
2 (<1%) of 250 patients
Tocilizumab
1 (<1%) of 250 patients
TNFi
1 (2%) of 57 patients
TNFi
1 (2%) of 57 patients
TNFi
1 (2%) of 57 patients
Abatacept
1 (2%) of 57 patients
Tocilizumab
1 (11%) of 9 patients
TNFi
1 (11%) of 9 patients
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arthritis starting a first biologic who subsequently switch 
biologic therapy, the extent of multiple switching, and with 
what pattern switching occurs. We also aimed to compare 
the effectiveness of different classes of biologics after 
switching from a first TNFi in routine clinical practice.
Methods
Study design and participants
We analysed data from two ongoing national biologic 
cohort studies of children and young people with juvenile 
idiopathic arthritis in the UK: the British Society for 
Paediatric and Adolescent Rheumatology Etanercept 
Cohort Study (BSPAR-ETN),11 established 2004, and the 
Biologics for Children with Rheumatic Diseases (BCRD) 
study,3 estab lished in 2010. Both studies use ident ical 
methodology, and patients can be switched between 
cohorts on the basis of the biologics received. Patients are 
tracked through the two studies to ensure all data can be 
combined and analysed for each unique patient.
Children and young people (aged <16 years) with 
physician-diagnosed juvenile idiopathic arth ritis, classi fied 
according to the International League of Associations for 
Rheumatology (ILAR) criteria12 are eligible for inclu sion 
in the studies and are recruited at the start of biologic 
therapy. Patients were not required to be biologic naive. We 
included all children and young people enrolled into BCRD 
or BSPAR-ETN between Jan 1, 2004, and April 11, 2019.
All participants or their legal guardians provided written 
informed consent in accordance with the Declaration of 
Helsinki. BSPAR-ETN was approved by the West Midlands 
Research Ethics Committee and BCRD was approved by 
the North West 7 REC Greater Manchester Central Ethics 
Committee.
Procedures
Baseline data were collected at the start of biological 
therapy, including patient demographics (age, gender-
identity), ILAR category, disease activity including active 
joint count (ie, swelling not caused by bony enlarge-
ment), limited joint count (limited range of motion plus 
tenderness, pain, or heat), physician’s global assess-
ment of overall disease activity (assessed using a visual 
analogue scale [0–10 cm]), patient (or parent) global 
assessment of overall wellbeing (PtGE; assessed using 
a visual analogue scale [0–10 cm]), erythrocyte sedi-
mentation rate, C-reactive protein concentration, pain 
(assessed using a visual analogue scale [0–10 cm]), 
functional ability (assessed using the Childhood Health 
Assessment Questionnaire [CHAQ]), previous and 
current conventional synthetic therapy, and history of 
uveitis. Follow-up data were obtained from patient medical 
records by the prescribing team and transferred to the 
study database via online web system at 6 months, 1 year, 
and annually thereafter, and included changes to disease 
activity, changes to antirheumatic therapies (includ ing 
start dates, stop dates, and reasons for cessation of 
therapy), and adverse events. For patients who switched 
biologic therapy, an additional form was used to collect 
data on disease activity at the time of switch and 6 months 
after switching.
Statistical analysis
We split the data analysis into two parts: assessment of 
biologic switching patterns in all children who started 
their first biologic from Jan 1, 2010, and assessment of 
response to a second biologic, in all children who started 
their first biologic from Jan 1, 2004.
Figure 2: Biologic switching in patients with systemic juvenile idiopathic arthritis who started treatment with a first biologic from Jan 1, 2010, onwards (n=97)
TNFi=tumour necrosis factor inhibitor. IL=interleukin.
TNFi
14 (14%) of 97 patients
IL-1 inhibitor
1 (25%) of 4 patients
IL-1 inhibitor
1 (25%) of 4 patients
Tocilizumab
1 (50%) of 2 patients
TNFi
1 (50%) of 2 patients
TNFi
1 (5%) of 20 patients
Tocilizumab
1 (5%) of 20 patients
IL-1 inhibitor
28 (29%) of 97 patients
TNFi
1 (5%) of 20 patients
Tocilizumab
8 (40%) of 20 patients
Tocilizumab
55 (57%) of 97 patients
IL-1 inhibitor
1 (25%) of 4 patients
IL-1 inhibitor
1 (25%) of 4 patients
TNFi
3 (15%) of 20 patients
IL-1 inhibitor
6 (30%) of 20 patients
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All children who initiated treatment with their first 
biologic from Jan 1, 2010, onwards, were included in the 
first part of the analysis. We used this date for two reasons: 
children starting non-etanercept biologics as their first 
biologic were only recruited from 2010 (before 2010, the 
studies were limited to children starting etanercept only), 
and a previous analysis based on these cohorts3 has shown 
that the pattern of biologic prescribing has changed over 
time, not only with regard to the choice of biologic, with a 
shift towards more non-etanercept biologics for children 
with certain disease features (ie, those with uveitis, or 
systemic juvenile idiopathic arthritis), but also towards 
earlier use of biologics. Thus, this date is more reflective 
of current biologic prescribing in patients with juvenile 
idiopathic arthritis. Patients were censored on the date of 
last study follow-up, date of death, or April 11, 2019 (data 
analysis cutoff), whichever came first. We calculated the 
propor tion of patients who switched biologics at least 
once, and median time from initiation of first biologic to 
the initiation of a second, third, and fourth biologic. All 
biologics currently available for the treat ment of inflam-
matory arthritis in children and adults were included, 
regardless of whether they were licensed specific ally for 
juvenile idiopathic arthritis. Patterns of biologic switching 
were also stratified by whether patients had systemic 
juvenile idiopathic arthritis.
For the second part of the analysis, we included all 
children who initiated treatment with their first biologic 
from Jan 1, 2004, onwards, and had polyarticular course 
juvenile idiopathic arthritis (extended oligoarthritis or 
polyarthritis [positive or negative for rheumatoid factor]) 
with no active uveitis at the time of initiation of their 
second biologic. We applied the inclusion criterion 
because we hypothesized that a diagnosis of active uveitis 
or systemic juvenile idiopathic arthritis would limit the 
choice of biologic. We used linear regression to assess 
the change in outcome variables (active joint count; 
limited joint count; physician’s global assessment of over-
all disease activity, PtGE, CHAQ, pain, erythrocyte sedi-
menta tion rate, and C-reactive protein concentration) and 
Juvenile Arthritis Disease Activity Score assessed in 
71 joints (JADAS-71;13 composite score of the active joint 
count, physician’s global assessment of disease activity, 
PtGE, and normal ised erythrocyte sedimentation rate) 
between the time of initiation of a second biologic and 
6 months thereafter, accounting for baseline values. 
Additionally, we assessed the American College of 
Rheumatology Paediatric (ACR Pedi) 90 response14— ie, 
the proportion of patients who achieve at least 90% 
improvement in at least three of the six core outcome 
variables (with no more than one worsening by more than 
30%)—and the proportion of patients who achieved 
minimal disease activity (defined as physician’s global 
assessment score ≤3·4; PtGE score ≤2·1, and ≤1 active 
joint15). Change in core outcome variables, JADAS-71 
score, and the proportion of patients who achieved ACR 
Pedi 90, and minimal disease activity at 6 months was 
Second TNFi 
(n=194)
Other biologic 
(n=46)
Gender
Female 153 (79%) 42 (91%)
Male 41 (21%) 4 (9%)
ILAR disease category at initiation of first TNFi
Extended oligoarthritis 64 (33%) 10 (22%)
Polyarthritis (negative for 
rheumatoid factor)
98 (51%) 27 (59%)
Polyarthritis (positive for 
rheumatoid factor)
32 (16%) 9 (20%)
First TNFi
Etanercept 158 (81%) 30 (65%)
Infliximab 10 (5%) 4 (9%)
Adalimumab 26 (13%) 12 (26%)
Disease duration at time of initiation 
of first TNFi (years)
2 (1–5)* 2 (1–6)
Reason for cessation of first biologic
Ineffectiveness 117 (60%) 27 (59%)
Adverse events (excluding 
uveitis) or intolerance
36 (19%) 7 (15%)
Ineffectiveness and intolerance 23 (12%) 7 (15%)
Patient decision (injection 
related)
9 (5%) 3 (7%)
Other 9 (5%) 2 (4%)
Time since initiation of first TNFi 
(years)
1·1 (0·5–2·5) 1·0 (0·7–3·5)
Start year of second biologic
Before 2010 23 (12%) 1 (2%)
2010–15 77 (40%) 19 (41%)
2016–19 94 (48%) 26 (57%)
Age at initiation of second biologic 
(years)
12 (9–15) 12 (9–15)
Disease duration at time of 
initiation of second biologic (years)
4 (2–7)* 5 (2–8)
Second biologic
Etanercept 10 (5%) 0
Infliximab 70 (36%) 0
Adalimumab 114 (59%) 0
Rituximab 0 6†(13%)
Tocilizumab 0 33 (72%)
Abatacept 0 6 (13%)
Ustekinumab 0 1 (2%)
Concomitant steroids within 
2 weeks of initiation of second 
biologic
52/152 (34%) 7/35 (20%)
Concomitant methotrexate 132 (68%) 30 (65%)
Active joint count (71 joints)
Patients with available data 176 (91%) 43 (93%)
Median (IQR) 3 (1–6) 3 (1–9)
Limited joint count (71 joints)
Patients with available data 174 (90%) 43 (93%)
Median (IQR) 2 (0–6) 2 (0–5)
Physician’s global assessment of disease activity (0–10 cm VAS)
Patients with available data 131 (68%) 29 (63%)
Median (IQR) 3 (2–4) 4 (2–6)
(Table 1 continues on next page)
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compared between patients starting a second TNFi and 
those switching to an alternative class of biologic using 
linear regression (for core outcome variables and 
JADAS-71 score) or logistic regression, adjusting for pro-
pensity quintiles to account for con founding by indica-
tion.16 For the ACR Pedi 90 response and minimal disease 
activity outcomes, patients who stopped biologic therapy 
before measure ment of the 6-month outcomes were 
classified as non-responders, with the exception of 
patients who stopped treatment due to remission (as 
reported by the clinician) who were classified as 
responders. We used Kaplan-Meier curves to assess the 
duration of treatment with a second biologic during the 
first 2 years of treatment after initiation of a second 
biologic, using propensity quintile adjusted Cox-
regression to compare the treatment dura tion between 
patients starting a second TNFi and those switching to 
another class of biologic. Reason for cessation of treatment 
with a second biologic by 2 years was compared between 
patients on a second TNFi and those on an alternative 
class of biologic using χ² tests. We did two sensitivity 
analyses comparing changes in outcome vari ables, 
JADAS-71, and the proportion of patients achieving ACR 
Pedi 90 and minimal disease activity: the first analysis was 
limited to patients who initiated treatment with a second 
TNFi or tocilizumab after failure of an initial TNFi, and 
the second was limited to only patients who stopped 
treatment with their initial TNFi due to ineffectiveness.
We used multiple imputation (83 iterations based on the 
proportion of incomplete cases17) to account for missing 
data. We calculated propensity scores and strati fied them 
into quintiles to include as an indicator variable in the 
regress ion models. The following variables included in the 
propensity score were measured at the time of initiation of 
a second biologic: second biologic start year (before 2010, 
2010–15, or 2016–18), time since initiation of first biologic, 
gender, ILAR category, age, disease duration, concomitant 
methotrexate, con comitant steroids, active joint count, 
limited joint count, physician’s global assessment, PtGE, 
CHAQ, pain, erythrocyte sedi mentation rate, c-reactive 
protein concentration, and JADAS-71 score.
We used Stata software (version 14.0) for all analyses.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results 
Between Jan 1, 2004, and April 11, 2019, 2361 patients 
were enrolled on initi ation of biologic therapy.
1152 patients (1055 with juvenile idiopathic arthritis; 
97 with systemic juvenile idiopathic arthritis) initiated 
treatment with their first biologic from Jan 1, 2010, 
onwards, of whom 1081 (95%; of 1132 patients with 
available data) reported previous treatment with metho-
trexate. 1050 (91%) of 1152 patients started initial treatment 
with a TNFi, although among the 97 patients with systemic 
juvenile idiopathic arthritis, IL-6 and IL-1 inhibitors were 
the most common first biologic therapy (55 [57%] patients 
initiated treatment with the IL-6 inhibitor tocilizumab; 
28 [29%] patients initiated treatment with an IL-1 inhibitor). 
A total of 2988 person-years of observed follow-up was 
available and the median duration of follow-up per patient 
was 2·2 years (IQR 1·1–3·8; maximum 9·1 years). During 
follow-up, 56 (5%) of 1152 patients withdrew or were lost to 
follow-up and 137 (12%) moved to an adult clinic where 
data capture from the adult hospital had not yet been 
established. 270 (23%) of 1152 patients started a second 
biologic after a median time of 1·3 years (IQR 0·6–2·3) 
from initiation of the first biologic, 61 (5%) patients started 
a third biologic after a median time of 2·5 years 
(IQR 1·6–3·7) from initiation of the first bio logic, and 
11 (1%) patients started a fourth biologic after a median 
time of 3·7 years (IQR 2·4–5·1) from initiation of the 
first biologic.
Of the 270 patients who started a second biologic, 
163 (60%) switched due to ineffectiveness and 66 (24%) 
switched due to adverse events (other reason or data 
missing for 41 [15%] patients). Of 1055 patients without 
Second TNFi 
(n=194)
Other biologic 
(n=46)
(Continued from previous column)
Patient’s or parent’s global assessment of wellbeing (0–10 cm VAS)
Patients with available data 130 (67%) 32 (70%)
Median (IQR) 5 (1–6) 5 (2–7)
Childhood Health Assessment Questionnaire score (range 0–3)
Patients with available data (n) 134 (69%) 36 (78%)
Median (IQR) 0·9 (0·3–1·6) 1·1 (0·3–1·6)
Pain (0–10 cm VAS)
Patients with available data (n) 128 (66%) 32 (70%)
Median (IQR) 5 (2–7) 5 (2–7)
Erythrocyte sedimentation rate (mm/h)
Patients with available data (n) 159 (82%) 35 (76%)
Median (IQR) 10 (5–19) 10 (5–21)
C-reactive protein concentration (mg/L)
Patients with available data (n) 170 (88%) 44 (96%)
Median (IQR) 5 (4–7) 4 (1–5)
JADAS-71 score
Patients with available data 91 (47%) 18 (39%)
Median (IQR) 11 (6–17) 12 (5–22)
TNFi=tumour necrosis factor inhibitor. ILAR=International League Against 
Rheumatism. VAS=visual analogue scale. JADAS-71=Juvenile Arthritis Disease 
Activity Score assessed in 71 joints. Data are n (%), median (IQR), or n/N (%), 
unless specified otherwise. *Data were missing for three patients. †Two of 
six patients were positive for rheumatoid factor. 
Table 1: Baseline characteristics of patients with polyarticular course 
juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis 
[positive or negative for rheumatoid factor]) who started a second 
biologic following initial TNFi (n=240)
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systemic juvenile idopathic arthritis disease, 250 patients 
started a second biologic. 247 (99%) of these 250 patients 
had initiated treatment with a first TNFi biologic, of whom 
202 (82%) started a second TNFi, whereas 45 (18%) 
switched from a TNFi to another class of biologic (figure 1). 
Of the 20 patients with systemic juvenile idiopathic 
arthritis who started a second biologic, eight (40%) patients 
started tocilizumab following initial treatment with an 
IL-1 inhib itor and six (30%) initiated treatment with an 
IL-1 inhibitor after initial treatment with tocilizumab 
(figure 2).
Of the 61 patients who started a third biologic, 24 (39%) 
switched due to repeated ineffectiveness, and 20 (33%) 
switched due to ineffectiveness and adverse events (other 
reason or data missing for 17 [28%] patients). Of the 
57 patients without systemic juve nile idiopathic arthritis, 
33 (58%) started tocilizumab, four (7%) started abatacept, 
and four (7%) started ritux imab following two previous 
TNFis, although seven (12%) patients switched to a third 
TNFi. Four (4%) patients with systemic juvenile idio -
pathic arthritis started a third biologic, all of which were 
IL-1 inhibitors.
Of the 11 patients who started a fourth biologic, 
four (36%) switched due to repeated ineffectiveness and 
six (55%) switched due to ineffectiveness and adverse 
events (other reason or data missing for one [9%] patient). 
Six (55%) of 11 patients started either their third or fourth 
class of biologic. Of the 270 patients who had been 
exposed to at least two different biologic therapies, 
25 (9%) patients had re-tried a biologic they had previously 
been treated with.
2361 patients were exposed to biologic therapy since 
Jan 1, 2004, and thus were eligible for inclusion in the 
second part of our data analysis (assessment of response 
to a second biologic). Of these 2361 patients, 
817 (35%) patients reported switching to a second biologic, 
of whom 282 (35%) had polyarticular course juvenile 
idiopathic arthritis (oligo articular extended or polyarticular 
[positive or negative for rheumatoid factor]) and had 
outcome data available. 42 of these 282 patients had active 
uveitis and were excluded. Thus, 240 patients were 
included in the analysis of response to a second biologic: 
194 (81%) of 240 started a second TNFi, and 46 (19%) 
started an alternative class of biologic (tocilizumab [n=33], 
abatacept [n=6], rituximab [n=6], and the IL-12 and IL-23 
inhibitor ustekinumab [n=1]). Patient char acteristics at the 
initiation of a second biologic were similar between those 
who were starting treatment with a second TNFi and those 
switching to another class of biologic (table 1), including 
the reason for discontinuation of the first biologic.
At 6 months (median follow-up 0·56 years 
[IQR 0·45–0·75]), no differences were identified with 
regard to change in individual outcome variables or 
JADAS-71 score between patients who started a second 
TNFi and those who initiated treatment with an alternative 
class of biologic (table 2). Among the 240 patients with 
polyarticular course juvenile idiopathic arthritis, a total of 
22% (95% CI 16–28) of patients achieved an ACR Pedi 90 
response, and 29% (23–36) of patients achieved minimal 
disease activity. No differences were identified in the 
Second TNFi
(n=194)
Other biologic
(n=46)
p value
Active joint count (71 joints)
Baseline 5·3 (0·5) 5·0 (0·9) 0·77
6 months 2·3 (0·3) 2·7 (0·8) 0·61
Difference* –2·9 (0·5)† –2·2 (1·0)† ..
Unadjusted β coefficient (95% CI) –0·5 (–1·8 to 0·9) 1 (ref) 0·51
Propensity quintile adjusted β coefficient (95% CI)‡ –0·6 (–2·9 to 1·8) 1 (ref) 0·64
Limited joint count (71 joints)
Baseline 4·5 (0·5) 3·8 (0·8) 0·47
6 months 3·3 (0·5) 2·4 (0·9) 0·43
Difference* –1·2 (0·6)† –1·4 (1·2)† ..
Unadjusted β coefficient (95% CI) 0·7 (–1·6 to 2·9) 1 (ref) 0·55
Propensity quintile adjusted β coefficient (95% CI)‡ 0·2 (–2·6 to 3·0) 1 (ref) 0·89
Physician’s global assessment of disease activity (VAS 0–10 cm)
Baseline 3·1 (0·2) 3·8 (0·4) 0·11
6 months 1·8 (0·2) 2·5 (0·4) 0·081
Difference* –1·4 (0·2)† –1·3 (0·5)† ..
Unadjusted β coefficient (95% CI) –0·6 (–1·4 to 0·2) 1 (ref) 0·17
Propensity quintile adjusted β coefficient (95% CI)‡ –0·7 (–1·7 to 0·3) 1 (ref) 0·16
PtGE (VAS 0–10 cm)
Baseline 4·1 (0·2) 4·6 (0·5) 0·43
6 months 2·9 (0·2) 3·8 (0·6) 0·089
Difference* –1·2 (0·3)† –0·7 (0·6)† ..
Unadjusted β coefficient (95% CI) –0·8 (–1·8 to 0·3) 1 (ref) 0·14
Propensity quintile adjusted β coefficient (95% CI)‡ –0·8 (–2·1 to 0·4) 1 (ref) 0·19
CHAQ score (range 0–3)
Baseline 1·03 (0·07) 1·10 (0·13) 0·63
6 months 0·89 (0·07) 1·02 (0·15) 0·40
Difference* –0·14 (0·06)† –0·08 (0·14)† ..
Unadjusted β coefficient (95% CI) –0·1 (–0·3 to 0·2) 1 (ref) 0·52
Propensity quintile adjusted β coefficient (95% CI)‡ –0·04 (–0·3 to 0·2) 1 (ref) 0·80
Pain (VAS 0–10)
Baseline 4·6 (0·3) 4·5 (0·5) 0·89
6 months 3·6 (0·2) 3·9 (0·5) 0·58
Difference* –1·0 (0·3)† -0·6 (0·6)† ..
Unadjusted β coefficient (95% CI) –0·3 (–1·4 to 0·7) 1 (ref) 0·51
Propensity quintile adjusted β coefficient (95% CI)‡ –0·4 (–1·7 to 0·8) 1 (ref) 0·50
Erythrocyte sedimentation rate (mm/h)
Baseline 18 (1·7) 16 (3·5) 0·73
6 months 12 (1·1) 9 (2·4) 0·21
Difference* –5·4 (1·6)† –7·2 (3·7)† ..
Unadjusted β coefficient (95% CI) 2·7 (–1·8 to 7·2) 1 (ref) 0·24
Propensity quintile adjusted β coefficient (95% CI)‡ 2·4 (–4·8 to 9·7) 1 (ref) 0·51
C-reactive protein concentration (mg/L)
Baseline 14 (2·2) 6·9 (2·2) 0·10
6 months 7·6 (1·3) 4·2 (1·6) 0·20
Difference* –6·5 (2·0)† –2·6 (2·7)† ..
Unadjusted β coefficient (95% CI) 1·2 (–3·2 to 5·7) 1 (ref) 0·58
Propensity quintile adjusted β coefficient (95% CI)‡ 0·9 (–6·6 to 8·4) 1 (ref) 0·82
(Table 2 continues on next page)
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proportion of patients who achieved an ACR Pedi 90 
response (odds ratio [OR] 2·5, 95% CI 0·8–7·9; p=0·11), or 
minimal disease activity (OR 1·6, 95% CI 0·6–3·8; p=0·33) 
between patients starting a second TNFi versus an alterna-
tive class of biologic, adjusted for propensity quintiles.
At 1 year, 63% (95% CI 55–68) of patients remained on 
their second biologic therapy and at 2 years, 42% (35–49) of 
patients remained on their second biologic therapy 
(figure 3). Propensity adjusted Cox-regression identified no 
significant differences in treatment duration with second 
biologic between patients on a second TNFi and patients 
on an alternative class of biologic (p=0·62). By 2 years, 
55 (44%) of 124 patients had stopped their second biologic 
due to ineffectiveness and 17 (14%) due to adverse events, 
with no differences identified between the two cohorts.
Sensitivity analyses of patients who switched from their 
first biologic to a second TNFi or tocilizumab, and patients 
who started a second biologic due to ineffectiveness 
showed that at 6 months, no differences were identified in 
individual outcome variables or JADAS-71, or the pro-
portion of patients who achieved ACR Pedi 90 or minimal 
disease activity between patients who initiated treat-
ment with a second TNFi and those who initiated treatment 
with an alternative class of bio logic in either analysis, 
adjusted for propensity quintiles (appendix pp 1–4).
Discussion
To our knowledge, this is the first observational study to 
report on the extent of multibiologic switching in a cohort 
of children and young people with juvenile idiopathic 
arthritis, and to compare the effectiveness of different 
biologics after the failure of a first biologic. Biologic 
switching was common, with 23% of patients receiving at 
least two biologics, 5% receiving at least three, and 1% 
receiving at least four biologics during a median follow-up 
time of 2·2 years from initiation of their first biologic. 
However, there was no evidence that among children with 
polyarticular course juvenile idiopathic arthritis for whom 
treatment with a first biologic was ineffective, that switch-
ing classes of biologic was more beneficial than initiation 
of treatment with a second biologic within the same class.
Although the majority of patients with juvenile idio-
pathic arthritis tolerate biologic treatment well and have 
sustained disease control,18 some patients do not respond 
to, or cannot tolerate treatment. Estimating the propor-
tion of patients with juvenile idiopathic arthritis who 
switch biologics multiple times allows appropriate service 
development and cost considerations. The use of data 
from a real-world cohort study is particularly valuable 
since these finding are representative of national pre-
scribing patterns. The proportion of patients switching to 
a second biologic in our study was similar to that of a 
Dutch registry (26%),7 but the proportion of patients with 
systemic juvenile idiopathic arthritis who started a second 
biologic was lower than that in a French retrospective 
study (44%).19 The majority of patients recruited in the 
previous Dutch and French cohort studies started 
Figure 3: Kaplan-Meier analysis of duration of treatment in patients with 
polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or 
polyarthritis [positive or negative for rheumatoid factor]) who started 
treatment with a second biologic after an initial TNFi (n=240)
TNFi=tumour necrosis factor inhibitor. Patients were censored at the date of last 
clinic visit, analysis cutoff (April 11, 2019), or death, whichever came first, 
whichever came first. Shaded areas represent 95% CIs.
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JADAS-71 score
Baseline 13 (0·8) 14 (1·4) 0·68
6 months 7·3 (0·6) 9·4 (1·3) 0·10
Difference* –5·9 (0·8)† -4·5 (1·6)† ..
Unadjusted β coefficient (95% CI) –1·9 (–4·3 to 0·5) 1 (ref) 0·12
Propensity quintile adjusted β coefficient (95% CI)‡ –2·2 (–5·8 to 1·4) 1 (ref) 0·23
Proportion of patients who achieved ACR Pedi 90 (%)§
6 months (95% CI) 24% (17 to 31) 13% (2 to 25) ..
Unadjusted OR (95% CI) 2·1 (0·7 to 6·2) 1 (ref) 0·17
Propensity quintile adjusted OR (95% CI)‡ 2·5 (0·8 to 7·9) 1 (ref) 0·11
Proportion of patients who achieved minimal disease activity (%)§
6 months (95% CI) 31% (23 to 38) 23% (9 to 37) ..
Unadjusted OR (95% CI) 1·5 (0·7 to 3·5) 1 (ref) 0·31
Propensity quintile adjusted OR (95% CI)‡ 1·6 (0·6 to 3·8) 1 (ref) 0·33
Date are mean (SE) or %, unless otherwise stated. Multiple imputation (83 datasets) was used to account for missing 
data. TNFi=tumour necrosis factor inhibitor. VAS=visual analogue scale. PtGE=patient’s or parent’s global assessment 
of overall wellbeing. CHAQ=childhood health assessment questionnaire. JADAS-71=Juvenile Arthritis Disease Activity 
Score assessed in 71 joints. ACR=American College of Rheumatology. ACR Pedi 90=ACR paediatric criteria for 
90% improvement. OR=odds ratio. ILAR=International League Against Rheumatism. *From time of initiation of 
second biologic to 6 months thereafter, accounting for baseline values. †Significant change in variable between 
baseline and 6 months (p<0·05). ‡Propensity quintile adjusted for the following variables at the time of initiation of 
second biologic: second biologic start year (before 2010, 2010–2015, or 2016–2018), time since initiation of first 
biologic, gender, ILAR category, age, disease duration, concomitant methotrexate, concomitant steroids, active joint 
count, limited joint count, physician’s global assessment of overall disease activity, patient (or parent) evaluation of 
overall wellbeing, CHAQ, pain, erythrocyte sedimentation rate, C-reactive protein concentration, and JADAS-71 score. 
§For ACR Pedi 90 and minimal disease activity outcomes, patients who stopped biologic therapy before the 6-month 
outcome measurements were completed were classified as non-responders and those who stopped because they had 
achieved remission were classified as responders.
Table 2: 6-month outcomes of patients with polyarticular course juvenile idiopathic arthritis (extended 
oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]) who started a second 
biologic (n=240)
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treatment with their first biologic before 2010 and 
therefore might not be representative of current biologic 
prescribing patterns. Whether a treat-to-target approach 
was specifically applied in some centres is unknown, thus 
it is unclear whether outcomes would be different if a 
specific treat-to-target guideline20,21 was used, but is worth 
considering in future research whether such an approach 
was used and whether outcomes improve overall with 
such an approach. Patients who do not respond to biologic 
therapy are likely to require increased medical input 
compared with patients who respond to biologic therapy 
due to increased fre quency of flares and increased need 
for drug education and monitoring.
In adults with rheumatoid arthritis, evidence supports 
switching from an initial TNFi to rituximab rather than a 
second TNFi.22 Evidence also indicates that in patients 
with exposure to at least one biologic, tocilizumab and a 
TNFi have similar effectiveness,23 as do rituximab and 
tocilizumab after initial treatment with a TNFi.24 However, 
rituximab is not a licensed treatment for children and 
young people with juvenile idiopathic arthritis and no 
formal controlled trials of rituximab in juvenile idiopathic 
arthritis have been done, thus the choice of approved 
biologics available remains limited. Most patients switch 
to a second TNFi, with many patients cycling onto their 
third TNFi despite the availability of alternative biologic 
therapies. The reasons for these choices are not known 
but the presence of uveitis might influence the choice of 
drug in some children.3 At present, two guidelines are 
available for biologic treatment of children and young 
people with juvenile idiopathic arth ritis for whom an 
initial TNFi was ineffective. Both guidelines recommend 
contradictory treatment pathways: NHS England5 recom-
mend patients switch to a second TNFi, whereas ACR10 
recommend switching to a non-TNFi (tocilizumab or 
abatacept). Additionally, the NHS guide lines recommend 
that patients who are positive for rheumatoid factor 
should switch to rituximab instead of a TNFi, consistent 
with adult practice, whereas the ACR guidelines speci-
fically recommend avoidance of this therapy, preferring 
the use of other classes primarily.
This study is a national cohort study and, although not 
mandatory, recruitment is recommended for all patients 
starting a biologic therapy5 and children have been rec-
ruited from almost every centre treating children with 
juvenile idiopathic arthritis in the UK. The study captures 
longitudinal prospective data from first biologic treatment, 
with the ability to track biologic switching. The use 
of robust statistical methods enabled the investigation 
of multiple outcomes in this analysis. However, juvenile 
idiopathic arthritis is a relatively rare disease with only 
20% of patients estimated to start biologic therapy within 
the first 3 years after diagnosis,25 with one-fifth of these 
patients switching to a second biologic. Therefore, this 
analysis might not be powered to detect smaller differences 
in outcome, or differences between individual biologic 
therapies. The sensitivity analysis aimed to remove some 
of the heterogeneity from the other biologic drug classes, 
although whether these would be clinically meaningful is 
unknown. Patient numbers were further limited by the 
lack of additional core outcome data collected at the time of 
biologic switch and at 6 months because these forms were 
not introduced until 2014. A sensitivity analysis limited to 
patients who started a second biologic due to ineffectiveness 
of initial TNFi was done, however a similar analysis limited 
to children who stopped treatment with a first biologic due 
to an adverse event was not possible due to small patient 
numbers. Additionally, 42 patients had active uveitis at the 
time of initiation of their second biologic and thus were 
excluded, since it was unclear whether these patients were 
starting the biologic to treat their arthritis or their uveitis. 
The study did not capture any data on treatment adher-
ence, drug levels, or anti-drug antibody concentrations, 
which might also influence treatment response. Further-
more, the route or frequency of biologic adminis tration 
was not investig ated, which might have also influenced 
treatment choice.
The time to initiation of a second biologic was more 
than 2·5 years after the initiation of a first TNFi in a 
quarter of children. For a rare disease such as juvenile 
idiopathic arthritis, it can take time to accumulate enough 
children for analysis and it is possible that outcomes 
might differ among children starting their second 
biologic in 2019, including quicker cycling through bio-
logics. This reduction in time to treatment could in turn 
have resulted in better overall responses to a second bio-
logic than those observed in the current study, although 
the proportion of adults with rheumatoid arthritis who 
respond well to a second biologic is lower than that with a 
first biologic.22
This is the first observational study to report that 
approximately one-fifth of children and young people with 
juvenile idiopathic arthritis in the UK starting their first 
biologic went on to receive a second biologic, and 5% 
received at least three biologics. Due to the frequent use 
of multiple TNFis, it is not possible to identify true 
multibiologic resistance in juvenile idiopathic arthritis, 
but the study shows that many children are being treated 
with multiple biologics. Additionally, among children 
with polyarticular course juvenile idiopathic arthritis for 
whom a first biologic was ineffective, no evidence was 
found to indicate that switching classes of biologic was 
more beneficial than initiation of treatment with a second 
bio logic within the same class, despite current ACR 
guidelines.10 Ideally, a randomised trial comparing dif-
ferent second biologics could help address this question 
with more certainty. Further study of patients requiring 
multiple biologics is vital to enable patient specific treat-
ment pathways, accurate prognosis discuss ions, and cost-
effectiveness analysis for service provisions. Additional 
controlled trials of biologic medica tions are required 
in juvenile idiopathic arthritis because the number of 
approved therapeutic options remains small compared 
with those available for rheumatoid arthritis.
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